Skip to main content
. Author manuscript; available in PMC: 2007 Jan 17.
Published in final edited form as: Ocul Surf. 2004 Oct;2(4):229–247. doi: 10.1016/s1542-0124(12)70111-8

Table 3.

Summary of Antimicrobial Peptides in Clinical Development

Company Peptide–Name Peptide–Origin Application Development Stage
Genaera (formerly Magainin) Pexiganan (Locilex) 22aa magainin Infected diabetic foot ulcers Denied FDA approval 1999
Intrabiotics Isegan Protegrin (a) Pneumonia in mechanically ventilated patients Phase III—stopped June 2004 for safety reasons
(b) Lung infection in cystic fibrosis Phase IIa
Micrologix MBI-226 No information Catheter related blood stream infection Phase III
MBI-594 No information Acne Phase IIb
Demgen (formerly Periodontix) P113D Histatin Lung infection in cystic fibrosis November 2002 Orphan drug designation
P113 Histatin Oral candadiasis in HIV Phase I/II
Xoma XMP-629 9aa fragment of BPI* Acne Phase II
Entomed ETD-151 Heliothis virescens Antifungal Preclinical
ETD-P1263 Insect defensin MRSA Preclinical
AmPharma No information No information (a) Systemic antibiotic/antifungal
(b) Incorporation in to surgical devices to prevent post-surgery infection		 Preclinical
*

BPI is bactericidal/permeability increasing protein, a 50–55kDa protein of neutrophils238